SYNTHETIC HELPER PEPTIDE VACCINES FOR PATIENTS WITH STAGE IV MELANOMA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol was designed to assess the safety and immunogenicity of a vaccine comprised of six melanoma helper peptides plus GM-CSF in adjuvant in patients with advanced melanoma. The objectives of this study are to determine if the vaccine (a) is safe, (b) will result in immune responses in the sentinel immunized node and peripheral blood, and (c) will result in delayed-type hypersensitivity response.